SCHEMBL5526644

SCHEMBL5526644

O=c1[nH]nnc2[nH]cnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
PDPK1 O15530 4/20 0.39
PARP1 P09874 6/20 0.38
BCL2 P10415 1/20 0.38
MCL1 Q07820 1/20 0.38
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
ADORA2A P29274 1/20 0.37
SLC6A4 P31645 1/20 0.37
ADRA1A P35348 1/20 0.37
XDH P47989 1/20 0.37
RAB9A P51151 1/20 0.37
BLM P54132 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PNP P00491 2/20 0.35
ACHE P22303 1/20 0.34
GDA Q9Y2T3 1/20 0.34
AURKA O14965 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hypoxanthine SCHEMBL30266940 0.71 TSHR (0.45) ALDH1A1PDPK1PARP1BCL2MCL1
SCHEMBL14094281 0.71 SMN1; SMN2 (0.46) ALDH1A1PDPK1PARP1BCL2MCL1
SCHEMBL30804836 0.71 ALDH1A1 (0.35) ALDH1A1PDPK1LMNATSHRADORA2A
SCHEMBL2473003 0.68 ALDH1A1 (0.64) ALDH1A1PDPK1LMNATSHRADORA2A
Hypoxanthine SCHEMBL31181347 0.67 ACHE (0.38) ALDH1A1PDPK1PARP1BCL2MCL1
Guanine SCHEMBL5259 0.64 ALDH1A1 (0.61) ALDH1A1PARP1LMNAXDHSMN1; SMN2
SCHEMBL8278860 0.64 PARP1 (0.43) ALDH1A1PDPK1PARP1PNPACHE
SCHEMBL19690932 0.64 PNP (0.41) ALDH1A1PDPK1PARP1BCL2MCL1
SCHEMBL21896056 0.64 PNP (0.41) ALDH1A1PDPK1PARP1BCL2MCL1
SCHEMBL4650483 0.64 PNP (0.41) ALDH1A1PDPK1PARP1BCL2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809328-B2 Imidazole derivative NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY (JP) 2014-08-19 US claimed
US-20140148598-A1 IMIDAZOLE DERIVATIVE NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY (JP) 2014-05-29 US claimed
EP-2703403-A1 IMIDAZOLE DERIVATIVE BASF SE (DE) 2014-03-05 EP claimed
US-12527801-B2 Cell activator of animal cell VITAMIN C60 BIORESEARCH CORPORATION (JP) 2026-01-20 US disclosed
EP-3960244-B1 CELL ACTIVATOR OF ANIMAL CELL VITAMIN C60 BIORESEARCH CORP (JP) 2025-04-09 EP disclosed
US-20250017918-A1 ORAL SUSPENSIONS COMPRISING TEMOZOLOMIDE OR LENALIDOMIDE SHORLA PHARMA LTD (IE) 2025-01-16 US disclosed
CN-112955116-B Cell activator for animal cells 维生素C60生化学研究公司 2023-10-27 CN disclosed
US-20220233547-A1 CELL ACTIVATOR OF ANIMAL CELL MITSUBISHI CORPORATION LIFE SCIENCES LIMITED (JP) 2022-07-28 US disclosed
EP-3960244-A1 CELL ACTIVATOR OF ANIMAL CELL Vitamin C60 Bioresearch Corporation (JP) 2022-03-02 EP disclosed
CN-112955116-A Cell activator for animal cells 维生素C60生化学研究公司 2021-06-11 CN disclosed
CN-112442036-A Novel purinone and imidazotriazinone derivatives having anti-glioma activity 南开大学 2021-03-05 CN disclosed
US-8232392-B2 Process for preparing temozolomide CHEMI S.P.A. (IT) 2012-07-31 US disclosed
US-20120122690-A1 Method For Increasing Yield Of Staple Food Crop NATIONAL UNIVERSITY CORPORATION SHIZUOKA (JP) 2012-05-17 US disclosed
US-20120122690-A1 Method For Increasing Yield Of Staple Food Crop NATIONAL UNIVERSITY CORPORATION SHIZUOKA (JP) 2012-05-17 US disclosed
EP-2374807-A2 An improved process for the isolation of temozolomide CIPLA LIMITED (IN) 2011-10-12 EP disclosed
US-20100036121-A1 Process for preparing temozolomide CHEMI S.P.A. (IT) 2010-02-11 US disclosed
US-20100036121-A1 Process for preparing temozolomide CHEMI S.P.A. (IT) 2010-02-11 US disclosed
US-20090326028-A1 Process for the preparation of temozolomide and analogs CIPLA LIMITED (IN) 2009-12-31 US disclosed
US-20090326028-A1 Process for the preparation of temozolomide and analogs CIPLA LIMITED (IN) 2009-12-31 US disclosed
WO-2008038031-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF TEMOZOLOMIDE AND ANALOGS CIPLA LIMITED (IN) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122690-A1 Method For Increasing Yield Of Staple Food Crop SI, H1-0, H1-3 ALDH1A1 4642/4885PDPK1 2241/4885PARP1 3223/4885
US-20140148598-A1 IMIDAZOLE DERIVATIVE ING2, DCUN1D5, IGF1R ALDH1A1 1509/4885PDPK1 608/4885PARP1 3604/4885
US-20220233547-A1 CELL ACTIVATOR OF ANIMAL CELL IL2, IL15, NFATC1 ALDH1A1 740/4885PDPK1 2783/4885PARP1 2122/4885
US-20090326028-A1 Process for the preparation of temozolomide and analogs IDH3A, IDH3B, IDH2 ALDH1A1 309/4885PDPK1 2709/4885PARP1 1663/4885
US-12527801-B2 Cell activator of animal cell DSG1, DSC1, KRT18 ALDH1A1 2037/4885PDPK1 844/4885PARP1 4313/4885
US-20100036121-A1 Process for preparing temozolomide MGMT, NNMT, NOS2 ALDH1A1 1519/4885PDPK1 4185/4885PARP1 441/4885
US-20250017918-A1 ORAL SUSPENSIONS COMPRISING TEMOZOLOMIDE OR LENALIDOMIDE MALT1, SMN1; SMN2, MGMT ALDH1A1 4194/4885PDPK1 1986/4885PARP1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.